Zadaxin Articles
SciClone and Sigma-Tau report promising Ph III Zadaxin data
18 February 2008
SciClone's Zadaxin shows broad mechanism
11 April 2005
Sharp rise in 3rd-qtr loss for SciClone
8 November 2004
Massive growth potential of China
6 September 2004
SciClone and Nektar form alliance
7 June 2004
SciClone earns $1M milestone from Sigma Tau
24 May 2004
Promising new data for SciClone's Zadaxin
1 March 2004
SciClone
12 May 2003
Sigma-Tau increases SciClone equity
3 February 2003
SciClone: positive Ph III data on HBV agent
11 March 2002
SciClone makes progress with Zadaxin in Japan
23 August 2001
SciClone gains Orphan Drug Status for Zadaxin
29 March 2000
Fujisawa and Elder sign marketing pact
2 March 2000
SciClone share boost on Zadaxin news
12 July 1999
Sigma-Tau licenses hepatitis drug Zadaxin
28 April 1999
-SciClone Pharmaceuticals' Zadaxin approvals
18 March 1999
SciClone's Zadaxin approved for hepatitis B and C in Venezuela
26 January 1999
Famvir Plus Zadaxin Beneficial In HBV
5 November 1998
First Appro For Zadaxin In Hep C
10 September 1998
S-P In Japan Begins Trial Of SciClone's Zadaxin
14 May 1998
Zadaxin May Have Wound-Healing Effects
16 March 1998
Hep C Drug Given Priority Status
22 January 1998
S-P Begins Ph II Zadaxin Trials
20 November 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
SciClone Reports New Data With Zadaxin
6 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
First Launch Of SciClone's Zadaxin In China
9 December 1996
SciClone's Zadaxin "Effective" In HCV
18 November 1996
Combination Therapy For HCV; Zadaxin
14 October 1996
SciClone's Zadaxin For HIV
22 July 1996
Philippines Appro For SciClone's Zadaxin
1 July 1996
Results From Taiwanese Zadaxin Study
18 March 1996
SciClone to repurchase common stock
8 January 1996
Results US Biopharmaceutical Firms Progress In Second Quarter
4 September 1995
Showing 1-37 of 37 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
